GGrantIndex
← Leaderboards

Eric B. Haura

H. Lee Moffitt Cancer Ctr & Res Inst

Google Scholar ↗PubMed ↗ORCID ↗
$11,744,471
Attributed
$17,198,640
Total exposure
17
Grants
13
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.1M · FY2007–25
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$36,304,099 · 19

By mechanism

P50$11,367,446 · 3
P01$10,093,168 · 1
R01$7,984,637 · 4
U01$2,290,499 · 1
R21$2,063,415 · 5
RC1$983,204 · 1

Top collaborators

Most similar at H. Lee Moffitt Cancer Ctr & Res Inst

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasm Of Lung”

Research focus

Malignant Neoplasm Of LungSignal TransductionTumorBaseMalignant NeoplasmsIn VivoPathway InteractionsResponseProgramsInhibitor/AntagonistMutationCellsNeoplastic CellResistanceCell LineCancer PatientEpidermal Growth Factor ReceptorCancer CellProteomicsXenograft ModelReceptorTyrosine Kinase InhibitorDrug ResistanceKinase Inhibitor

Grant awards (74)

Identifying Metabolic Vulnerabilities in Lung Cancer$2,032,950
P01 · FY2025 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$681,912
R01 · FY2025 · CA
Identifying Metabolic Vulnerabilities in Lung Cancer$1,951,918
P01 · FY2024 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$649,046
R01 · FY2024 · CA
Identifying Metabolic Vulnerabilities in Lung Cancer$2,019,244
P01 · FY2023 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$666,289
R01 · FY2023 · CA
Overcoming resistance to KRAS inhibitors through a fragment-based chemoproteomics approach$433,256
R21 · FY2023 · CA · contact PI
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$72,662
R01 · FY2023 · CA
Identifying Metabolic Vulnerabilities in Lung Cancer$2,029,016
P01 · FY2022 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$666,846
R01 · FY2022 · CA
Validation of EGFR Protein Complexes as Molecular Diagnostics$138,649
UH3 · FY2022 · CA · contact PI
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$74,145
R01 · FY2022 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$29,208
R01 · FY2022 · CA
Identifying Metabolic Vulnerabilities in Lung Cancer$2,060,040
P01 · FY2021 · CA
Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers$679,205
R01 · FY2021 · CA
Targeting bidirectional signaling in lung stroma and cancer cells$478,243
R01 · FY2021 · CA
Precision lung cancer therapy design through multiplexed adapter measurement$459,362
U01 · FY2021 · CA
Validation of EGFR Protein Complexes as Molecular Diagnostics$308,748
UH3 · FY2021 · CA · contact PI
Core 017 (502) Protocol Review and Monitoring System$77,539
P30 · FY2021 · CA · contact PI
Targeting bidirectional signaling in lung stroma and cancer cells$506,795
R01 · FY2020 · CA
Precision lung cancer therapy design through multiplexed adapter measurement$434,529
U01 · FY2020 · CA
Validation of EGFR Protein Complexes as Molecular Diagnostics$97,114
UH3 · FY2020 · CA · contact PI
Targeting bidirectional signaling in lung stroma and cancer cells$491,590
R01 · FY2019 · CA
Precision lung cancer therapy design through multiplexed adapter measurement$399,937
U01 · FY2019 · CA
Validation of EGFR Protein Complexes as Molecular Diagnostics$331,179
UH3 · FY2019 · CA · contact PI
Chemical Biology & Molecular Medicine$58,074
P30 · FY2019 · CA · contact PI
Precision lung cancer therapy design through multiplexed adapter measurement$550,445
U01 · FY2018 · CA
Targeting bidirectional signaling in lung stroma and cancer cells$526,874
R01 · FY2018 · CA
Applying Chemical Biology to Target Deubiquitinating Enzymes in Lung Cancer$187,050
R21 · FY2018 · CA · contact PI
Chemical Biology & Molecular Medicine$52,289
P30 · FY2018 · CA · contact PI
Chemical Biology & Molecular Medicine$8,049
P30 · FY2018 · CA · contact PI
Chemical Biology & Molecular Medicine$3,751
P30 · FY2018 · CA · contact PI
Chemical Biology & Molecular Medicine$3,288
P30 · FY2018 · CA · contact PI
Targeting bidirectional signaling in lung stroma and cancer cells$505,460
R01 · FY2017 · CA
Precision lung cancer therapy design through multiplexed adapter measurement$446,226
U01 · FY2017 · CA
Applying Chemical Biology to Target Deubiquitinating Enzymes in Lung Cancer$224,460
R21 · FY2017 · CA · contact PI
Chemical Biology & Molecular Medicine$52,287
P30 · FY2017 · CA · contact PI
Validation of EGFR Protein Complexes as Molecular Diagnostics$390,763
UH2 · FY2016 · CA · contact PI
AN ACTIVE ROLE OF ADAPTOR PROTEINS IN TYROSINE KINASE INHIBITOR RESISTANCE$183,244
R21 · FY2015 · CA · contact PI
AN ACTIVE ROLE OF ADAPTOR PROTEINS IN TYROSINE KINASE INHIBITOR RESISTANCE$219,893
R21 · FY2014 · CA · contact PI
ACTIVITY-BASED KINASE DISCOVERY IN SMALL CELL LUNG CANCER$182,868
R21 · FY2014 · CA · contact PI
ACTIVITY-BASED KINASE DISCOVERY IN SMALL CELL LUNG CANCER$233,096
R21 · FY2013 · CA · contact PI
SPORE in Lung Cancer$1,991,619
P50 · FY2012 · CA · contact PI
CDP - Career Development Program$400,000
P50 · FY2012 · CA · contact PI
P3 - Antitumor Mechanisms of SRC Inhibitors in Lung Cancer$400,000
P50 · FY2012 · CA · contact PI
PROTEIN PROTEIN INTERACTIONS AS BIOMARKERS$181,613
R21 · FY2012 · CA · contact PI
SPORE in Lung Cancer$94,360
P50 · FY2012 · CA · contact PI
SPORE in Lung Cancer$1,900,000
P50 · FY2011 · CA · contact PI
P3 - Antitumor Mechanisms of SRC Inhibitors in Lung Cancer$323,211
P50 · FY2011 · CA · contact PI
Stat3 in EGFR Driven Non-Small Cell Lung Cancer$307,781
R01 · FY2011 · CA · contact PI
PROTEIN PROTEIN INTERACTIONS AS BIOMARKERS$217,935
R21 · FY2011 · CA · contact PI
SPORE in Lung Cancer$135,386
P50 · FY2011 · CA · contact PI
CDP - Career Development Program$82,986
P50 · FY2011 · CA · contact PI
SPORE in Lung Cancer$2,000,000
P50 · FY2010 · CA · contact PI
A novel molecular diagnostic approach to classify lung cancers and predict respon$489,074
RC1 · FY2010 · CA
P3 - Antitumor Mechanisms of SRC Inhibitors in Lung Cancer$367,876
P50 · FY2010 · CA · contact PI
Stat3 in EGFR Driven Non-Small Cell Lung Cancer$317,300
R01 · FY2010 · CA · contact PI
SPORE in Lung Cancer$158,648
P50 · FY2010 · CA · contact PI
SPORE in Lung Cancer$158,568
P50 · FY2010 · CA · contact PI
CDP - Career Development Program$96,496
P50 · FY2010 · CA · contact PI
SPORE in Lung Cancer$2,000,000
P50 · FY2009 · CA · contact PI
A novel molecular diagnostic approach to classify lung cancers and predict respon$494,130
RC1 · FY2009 · CA
Antitumor Mechanisms of SRC Inhibitors in Lung Cancer$352,790
P50 · FY2009 · CA · contact PI
Stat3 in EGFR Driven Non-Small Cell Lung Cancer$316,667
R01 · FY2009 · CA · contact PI
SPORE in Lung Cancer$256,642
P50 · FY2009 · CA · contact PI
SPORE in Lung Cancer$158,568
P50 · FY2009 · CA · contact PI
SPORE in Lung Cancer$158,500
P50 · FY2009 · CA · contact PI
Career Development Program$94,505
P50 · FY2009 · CA · contact PI
Stat3 in EGFR Driven Non-Small Cell Lung Cancer$315,400
R01 · FY2008 · CA · contact PI
Antitumor Mechanisms of SRC Inhibitors in Lung Cancer$187,310
P50 · FY2008 · CA · contact PI
Antitumor Mechanisms of SRC Inhibitors in Lung Cancer$79,814
R01 · FY2008 · CA · contact PI
Career Development Program$49,981
P50 · FY2008 · CA · contact PI
Antitumor Mechanisms of SRC Inhibitors in Lung Cancer$309,700
R01 · FY2007 · CA · contact PI
Stat3 in EGFR Driven Non-Small Cell Lung Cancer$309,700
R01 · FY2007 · CA · contact PI